My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidlines Journals & Publications Policy & Advocacy Meetings About IDSA
July 2008
Volume 18, Number 7
Drug Approvals, Recalls, Adverse Events Update

IDSA offers two e-mail services to help members stay informed of updates from the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). Recent alerts have included:

  • Drug Information Update -- Fluroquinolone Antimicrobial Drugs
    “FDA is notifying the makers of fluoroquinolone antimicrobial drugs for systemic use of the need to add a boxed warning to the prescribing information about the increased risk of developing tendonitis and tendon rupture in patients taking fluoroquinolones…”

IDSA members can sign up for this service online. (You must be logged in to have access to this link.)

< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


New Encephalits Guidelines Published
HIV Opportunistic Infections Guidelines Updated
IDSA Journal Club, July 2008
In the IDSA Journals
ACIP Makes New Recommendations on Rabies, HPV, Pneumococcal Vaccines
CDC Updates Recommendations on Prevention, Control of Influenza
Zoster Vaccine Recommended for All Persons Over 60
EIN: MAI Disease and Clofazimine
Drug Approvals, Recalls, Adverse Events Update
Congress Stops Steep Medicare Physician Payment Cuts, For Now
CMS to Launch New Website to Compare Physicians
U.S. Global AIDS Program Expands
Federal ID Budgets Likely to See Small Increases
IDSA Advocacy Update: IDSA Opposes Federal Antiviral, Antibiotic Stockpiling Plans
IDSA/SHEA Infection Control Fellows Course Available Online
Looking For CME Opportunities?
Congratulations, New IDSA Fellows!
IDSA 2008 Elections Coming Up
Members on the Move
Welcome, New IDSA Members!
View archived IDSA News issues
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.